A detailed history of Kingswood Wealth Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Kingswood Wealth Advisors, LLC holds 21,906 shares of GILD stock, worth $1.84 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
21,906
Previous 11,494 90.59%
Holding current value
$1.84 Million
Previous $842 Million 78.51%
% of portfolio
0.14%
Previous 0.1%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 09, 2024

BUY
$63.15 - $72.88 $657,517 - $758,826
10,412 Added 90.59%
21,906 $1.5 Billion
Q1 2024

Apr 15, 2024

SELL
$71.58 - $87.29 $734,339 - $895,508
-10,259 Reduced 47.16%
11,494 $842 Million
Q4 2023

Jan 16, 2024

BUY
$73.27 - $83.09 $780,032 - $884,576
10,646 Added 95.85%
21,753 $1.76 Billion
Q3 2023

Oct 23, 2023

BUY
$73.94 - $80.67 $573,774 - $625,999
7,760 Added 231.85%
11,107 $832 Million
Q2 2023

Aug 09, 2023

BUY
$76.01 - $86.7 $254,405 - $290,184
3,347 New
3,347 $258 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $105B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Kingswood Wealth Advisors, LLC Portfolio

Follow Kingswood Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kingswood Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kingswood Wealth Advisors, LLC with notifications on news.